Pathos AI Closes $62M Series C to Accelerate Drug Development
29 Oct 2024 //
GLOBENEWSWIRE
Pathos Secures Worldwide License For Phase 2-ready PRMT5 Inhibitor
15 Aug 2024 //
GLOBENEWSWIRE
Pathos Launches Oncology Pipeline With License of First Phase I Program
23 May 2023 //
BUSINESSWIRE